CCL17 and melanoma: Increased expression of CD8+ granzyme B+ T cells has been correlated with higher transcript levels of CCL17, and higher serum levels of CCL17 were also associated with progression-free survival in advanced melanoma patients undergoing dendritic-cell-based immunotherapy [45].